Genmab A/S (GMAB) Revenue History
Annual and quarterly revenue from 2002 to present
GMAB Revenue Over Time (2002–2025)
GMAB Revenue Growth History
16 of 22 years with positive growth- FY2002 revenue growth
- N/A
- FY2003 revenue growth
- N/A
- FY2004 revenue growth
- -94.0%
- FY2005 revenue growth
- +2302.0%
- FY2006 revenue growth
- +37.6%
- FY2007 revenue growth
- +290.7%
- FY2008 revenue growth
- +40.7%
- FY2009 revenue growth
- -21.3%
- FY2010 revenue growth
- -0.7%
- FY2011 revenue growth
- -39.7%
- FY2012 revenue growth
- +38.1%
- FY2013 revenue growth
- +36.9%
- FY2014 revenue growth
- +28.2%
- FY2015 revenue growth
- +33.2%
- FY2016 revenue growth
- +60.3%
- FY2017 revenue growth
- +30.2%
- FY2018 revenue growth
- +27.9%
- FY2019 revenue growth
- +77.4%
- FY2020 revenue growth
- +88.4%
- FY2021 revenue growth
- -16.8%
- FY2022 revenue growth
- +72.3%
- FY2023 revenue growth
- +13.6%
- FY2024 revenue growth
- +30.7%
- FY2025 revenue growth
- -82.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $899.3M | +25.8% |
| Q4 2025 | $1.05B | -83.6% |
| Q3 2025 | $1.02B | -81.6% |
| Q2 2025 | $5.86B | +652.5% |
| Q1 2025 | $715.0M | +18.6% |
| Q4 2024 | $6.44B | +37.7% |
| Q3 2024 | $5.54B | +17.6% |
| Q2 2024 | $779.0M | -81.3% |
Multi-year avg. share of annual revenue by fiscal quarter
GMAB Revenue Analysis (2002–2025)
Current Revenue & Growth
As of June 22, 2026, Genmab A/S (GMAB) generated trailing twelve-month (TTM) revenue of $8.84 billion, reflecting exceptional growth of +25.8% year-over-year. The most recent quarter (Q1 2026) recorded $899.3 million in revenue, down 14.7% sequentially.
Historical Growth Trajectory
GMAB's 5-year compound annual growth rate (CAGR) stands at -18.1%, indicating revenue contraction over this period. The 3-year CAGR of -36.4% is below the 5-year average, signalling a growth deceleration in recent years. Genmab A/S's highest annual revenue of $21.53 billion was recorded in 2024.
Peer Comparison
Compared to Healthcare sector peers — including REGN (+5.9% YoY), SRPT (-2.2% YoY), and INCY (+21.5% YoY) — GMAB has outperformed the peer group in revenue growth. Compare GMAB vs REGN →
GMAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GMABCurrent | $8.8B | +25.8% | -18.1% | 33.6% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 INCY | $5.1B | +21.5% | +14.0% | 26.1% | |
 EXEL | $2.3B | +3.3% | +18.6% | 37.6% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% |
GMAB Historical Revenue Data (2002–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.72B | -82.7% | $3.41B | 91.7% | $1.25B | 33.6% |
| 2024 | $21.53B | +30.7% | $20.54B | 95.4% | $6.70B | 31.1% |
| 2023 | $16.47B | +13.6% | $16.25B | 98.6% | $5.32B | 32.3% |
| 2022 | $14.51B | +72.3% | $14.51B | 100.0% | $6.27B | 43.2% |
| 2021 | $8.42B | -16.8% | $8.42B | 100.0% | $2.95B | 35.1% |
| 2020 | $10.11B | +88.4% | $10.11B | 100.0% | $6.31B | 62.4% |
| 2019 | $5.37B | +77.4% | $5.37B | 100.0% | $2.64B | 49.2% |
| 2018 | $3.03B | +27.9% | $3.03B | 100.0% | $1.38B | 45.6% |
| 2017 | $2.37B | +30.2% | $2.37B | 100.0% | $1.34B | 56.8% |
| 2016 | $1.82B | +60.3% | $1.82B | 100.0% | $1.05B | 58.0% |
| 2015 | $1.13B | +33.2% | $1.13B | 100.0% | $730.4M | 64.5% |
| 2014 | $850.4M | +28.2% | $850.4M | 100.0% | $265.2M | 31.2% |
| 2013 | $663.6M | +36.9% | $663.6M | 100.0% | $69.3M | 10.4% |
| 2012 | $484.6M | +38.1% | $484.6M | 100.0% | $-116,679,000 | -24.1% |
| 2011 | $350.9M | -39.7% | $-181,571,000 | -51.7% | $-249,422,000 | -71.1% |
Full Stock Analysis
Deep dive into GMAB consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
Is GMAB's revenue growth accelerating or slowing?
GMAB revenue growth is accelerating. TTM revenue reached $8.8B, up +25.8% year-over-year — ahead of the 5-year CAGR of -18.1%. This indicates the business is expanding faster than its historical baseline.
What is GMAB's revenue history from 2002 to 2026?
Genmab A/S (GMAB) revenue history spans 2002 to 2026. TTM revenue as of 2026 is $8.8B, growing at +25.8% YoY. The 5-year CAGR is -18.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is GMAB's long-term revenue growth rate (CAGR)?
Genmab A/S's 5-year revenue CAGR of -18.1% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +25.8% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for GMAB.
Why does GMAB's quarterly revenue fluctuate?
GMAB quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Genmab A/S's revenue data from 2002 to 2026 shows full historical quarterly detail on this page.
How is GMAB's revenue distributed by segment?
GMAB reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does GMAB's revenue compare to industry peers?
Genmab A/S (GMAB) with TTM revenue of $8.8B and +25.8% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.